Millions of Americans taking Ozempic, Wegovy, Mounjaro, and related medications for diabetes and weight loss may face a modest increase in hair shedding, according to a major new study published in The BMJ.
Researchers analyzing five years of patient data from the University of Pennsylvania found that adults using GLP-1 receptor agonists developed hair loss at higher rates than those on other common diabetes treatments. While the absolute risk remains low, the findings suggest clinicians and patients should weigh this potential side effect when choosing medications.
GLP-1 drugs, which include semaglutide and tirzepatide, have revolutionized treatment for type 2 diabetes and obesity. Patients and social media users have reported hair loss anecdotally, but this is the first large-scale comparison showing how GLP-1 medications stack up against alternative treatments.
The research team examined electronic health records from roughly 27,000 diabetes patients treated between January 2019 and September 2024. They split patients into two main groups: one comparing GLP-1 users to those taking SGLT-2 inhibitors, and another comparing GLP-1 users to those on DPP-4 inhibitors.
The results showed a clear pattern. GLP-1 users developed alopecia at a rate of 6.91 cases per 1,000 person-years, compared to 5.04 cases for SGLT-2 inhibitor users. Against DPP-4 inhibitors, the difference was even starker: 6.53 versus 3.89 cases per 1,000 person-years. In statistical terms, that translates to a 37% higher risk in the first comparison and 68% higher in the second.
The study focused on non-scarring alopecia, the most common form of hair loss where follicles remain intact and hair can potentially regrow. The risk differences were consistent across this category.
What drives the connection remains unclear. The researchers point to rapid weight loss as a likely culprit, since GLP-1 drugs work partly by accelerating weight reduction. Shedding hair during quick weight loss is well documented in medical literature. The medications may also trigger iron or zinc deficiencies, both known to disrupt the hair growth cycle. Hormonal shifts accompanying weight loss could play a role too, though more research is needed to pin down mechanisms.
The study has limitations. Medical records lacked detail on how severe the hair loss was or how long it lasted. Researchers could not determine whether hair regrew after patients stopped taking the drugs. As an observational study, it cannot definitively prove GLP-1 medications caused the hair loss, only that the two are associated.
Still, the authors emphasized the study used high-quality data from a large, representative patient population and that findings held steady across multiple analyses. They described the work as rigorous and noted it transforms previous scattered patient reports into systematic evidence.
For patients weighing whether to start a GLP-1 drug, the absolute numbers matter. The increased risk exists, but remains low in real terms. A person might expect to see a few more cases of hair loss per thousand users per year, not a widespread epidemic. Yet for someone already dealing with hair thinning or concerned about appearance, that modest increase could tip the decision toward an alternative medication.
Clinicians now have stronger grounds to discuss this potential side effect upfront, allowing patients to make informed choices. The research also opens the door to future studies examining whether the hair loss is truly reversible and whether specific patient characteristics predict higher vulnerability.
Author Jessica Williams: "The study nails down what patients were already whispering about on social media, and that matters more than some might expect when you're asking someone to commit to a medication they may take for years."
Comments